Ultra-rapid lispro (URLi; Lyumjev) has an improved pharmacokinetic profile for exercise as compared to Humalog and results in less exercise-associated hypoglycemia in adults with type 1 diabetes on open-loop continuous subcutaneous insulin infusion (CSII).
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Fields of Study & Subjects
Publication details
- Publication date
- 26 March 2026
- Language
- EN